| DM |
2026-09-03 16:49 |
2026-09-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+9,104 |
25.3K |
+56% |
— |
| D |
2026-09-03 16:49 |
2026-09-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$79.28 |
-4,404 |
20.9K |
-17% |
-$349.1K |
| D |
2026-04-08 16:44 |
2026-04-07 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+2,694 |
17.5K |
+18% |
— |
| D |
2026-04-08 16:44 |
2026-04-07 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$48.94 |
-1,303 |
16.2K |
-7% |
-$63.8K |
| D |
2026-04-03 16:40 |
2026-04-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+5,187 |
17.3K |
+43% |
— |
| D |
2026-04-03 16:40 |
2026-04-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$48.13 |
-2,510 |
14.8K |
-15% |
-$120.8K |
| DM |
2026-03-11 |
2026-03-09 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$20.69 |
+36.7K |
48.8K |
+304% |
+$759.8K |
| DM |
2026-03-11 |
2026-03-09 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$45.92 |
-36.7K |
30.8K |
-54% |
-$1.69M |
| DM |
2026-02-11 |
2026-02-09 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$43.28 |
-17.8K |
12.1K |
-60% |
-$772.3K |
| DM |
2026-02-11 |
2026-02-09 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$13.87 |
+10.8K |
27.5K |
+65% |
+$150.4K |
|
2026-01-09 |
2026-01-08 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale |
$41.89 |
-12.0K |
19.1K |
-39% |
-$502.7K |
| DM |
2025-12-10 |
2025-12-08 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$11.34 |
+42.8K |
47.2K |
+972% |
+$486.0K |
| D |
2025-12-10 |
2025-12-08 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$41.49 |
-42.8K |
31.1K |
-58% |
-$1.78M |
| D |
2025-11-14 |
2025-11-12 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$30.93 |
+19.9K |
51.0K |
+64% |
+$615.5K |
| D |
2025-11-14 |
2025-11-12 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$40.94 |
-19.9K |
31.1K |
-39% |
-$814.7K |
| D |
2025-10-30 |
2025-10-28 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$30.93 |
+100 |
31.2K |
+0.3% |
+$3,093 |
| D |
2025-10-30 |
2025-10-28 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$41.00 |
-100 |
31.1K |
-0.3% |
-$4,100 |
| DM |
2025-09-03 |
2025-09-01+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+7,897 |
32.0K |
+33% |
— |
| DM |
2025-09-03 |
2025-09-01+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$33.68 |
-3,820 |
31.1K |
-11% |
-$128.6K |
| D |
2025-08-06 |
2025-08-04 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$22.89 |
+18.9K |
45.9K |
+70% |
+$432.4K |
| D |
2025-08-06 |
2025-08-04 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$32.89 |
-18.9K |
27.0K |
-41% |
-$621.3K |
| D |
2025-06-05 |
2025-06-03 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$28.80 |
-18.3K |
27.0K |
-40% |
-$527.0K |
| D |
2025-06-05 |
2025-06-03 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$18.00 |
+18.3K |
45.3K |
+68% |
+$329.4K |
| DM |
2025-05-01 |
2025-04-29+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$16.51 |
+88.4K |
47.0K |
New |
+$1.46M |
| DM |
2025-05-01 |
2025-04-29+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$26.56 |
-88.4K |
27.0K |
-77% |
-$2.35M |
| D |
2025-04-29 |
2025-04-26 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$21.37 |
-479 |
27.0K |
-2% |
-$10.2K |
| D |
2025-04-29 |
2025-04-26 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+990 |
27.5K |
+4% |
— |
| D |
2025-04-09 |
2025-04-07 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+2,694 |
27.8K |
+11% |
— |
| D |
2025-04-09 |
2025-04-07 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$20.28 |
-1,303 |
26.5K |
-5% |
-$26.4K |
| DM |
2025-04-03 |
2025-04-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$21.77 |
-1,617 |
25.9K |
-6% |
-$35.2K |
| DM |
2025-04-03 |
2025-04-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+3,342 |
25.1K |
+15% |
— |
| D |
2025-03-24 |
2025-03-20 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$12.97 |
+15.9K |
39.3K |
+68% |
+$206.8K |
| D |
2025-03-24 |
2025-03-20 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$23.11 |
-15.9K |
23.4K |
-41% |
-$368.5K |
| DM |
2025-03-19 |
2025-03-16+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$12.97 |
+21.2K |
34.8K |
+156% |
+$275.2K |
| D |
2025-03-19 |
2025-03-16 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$22.61 |
-448 |
23.4K |
-2% |
-$10.1K |
| DM |
2025-03-19 |
2025-03-17+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$23.10 |
-20.3K |
23.4K |
-47% |
-$469.9K |
| D |
2025-03-14 |
2025-03-12 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$22.25 |
-36.4K |
23.0K |
-61% |
-$809.3K |
| D |
2025-03-14 |
2025-03-12 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$11.97 |
+36.4K |
59.3K |
+158% |
+$435.4K |
| DM |
2024-12-10 |
2024-12-06+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$11.06 |
+21.3K |
41.8K |
+103% |
+$235.2K |
| DM |
2024-12-10 |
2024-12-06+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$21.34 |
-27.8K |
23.0K |
-55% |
-$594.0K |
| DM |
2024-12-05 |
2024-12-03+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$10.76 |
+15.1K |
24.1K |
+169% |
+$162.6K |
| DM |
2024-12-05 |
2024-12-03+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$21.37 |
-15.1K |
23.0K |
-40% |
-$323.0K |
| DM |
2024-09-04 |
2024-09-01+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$26.74 |
-3,216 |
23.0K |
-12% |
-$86.0K |
| DM |
2024-09-04 |
2024-09-01+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+6,305 |
23.9K |
+36% |
— |
| D |
2024-07-25 |
2024-07-23 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$11.10 |
+24.2K |
43.5K |
+126% |
+$269.2K |
| D |
2024-07-25 |
2024-07-23 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$24.79 |
-24.2K |
19.3K |
-56% |
-$601.1K |
| D |
2024-04-30 |
2024-04-26 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$17.88 |
-509 |
19.3K |
-3% |
-$9,101 |
| D |
2024-04-30 |
2024-04-26 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+991 |
19.8K |
+5% |
— |
| D |
2024-04-08 |
2024-04-08 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$17.90 |
-791 |
18.8K |
-4% |
-$14.2K |
| D |
2024-04-08 |
2024-04-08 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+2,694 |
19.6K |
+16% |
— |
| D |
2024-04-03 |
2024-04-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+1,750 |
17.4K |
+11% |
— |
| D |
2024-04-03 |
2024-04-01 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$19.70 |
-514 |
16.9K |
-3% |
-$10.1K |
| D |
2024-01-04 |
2024-01-03 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
$8.83 |
+12.0K |
27.6K |
+77% |
+$106.0K |
| D |
2024-01-04 |
2024-01-03 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
S - Sale+OE |
$20.00 |
-12.0K |
15.6K |
-43% |
-$240.0K |
| DM |
2023-09-06 |
2023-09-01+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$17.76 |
-1,338 |
15.6K |
-8% |
-$23.8K |
| DM |
2023-09-06 |
2023-09-01+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+4,556 |
16.2K |
+39% |
— |
| D |
2023-04-28 |
2023-04-26 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$11.15 |
-291 |
12.4K |
-2% |
-$3,245 |
| D |
2023-04-28 |
2023-04-26 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+990 |
12.7K |
+8% |
— |
| D |
2023-04-11 |
2023-04-10 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+2,695 |
12.5K |
+27% |
— |
| D |
2023-04-11 |
2023-04-10 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$10.71 |
-791 |
11.7K |
-6% |
-$8,472 |
| DM |
2023-03-20 |
2023-03-16+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+3,030 |
10.4K |
+41% |
— |
| DM |
2023-03-20 |
2023-03-16+ |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$11.22 |
-890 |
9,811 |
-8% |
-$9,984 |
| D |
2022-09-06 |
2022-09-02 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$11.44 |
-547 |
7,671 |
-7% |
-$6,258 |
| D |
2022-09-06 |
2022-09-02 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+1,861 |
8,218 |
+29% |
— |
| D |
2022-04-28 |
2022-04-26 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+991 |
6,639 |
+18% |
— |
| D |
2022-04-28 |
2022-04-26 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$9.99 |
-282 |
6,357 |
-4% |
-$2,817 |
| D |
2022-03-23 |
2022-03-21 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+3,019 |
6,695 |
+82% |
— |
| D |
2022-03-23 |
2022-03-21 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$10.98 |
-1,047 |
5,648 |
-16% |
-$11.5K |
| D |
2022-03-18 |
2022-03-16 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
F - Tax |
$10.13 |
-303 |
3,676 |
-8% |
-$3,069 |
| D |
2022-03-18 |
2022-03-16 |
KNSA |
Kiniksa Pharmaceuticals International, plc |
Ragosa Mark |
CFO |
M - OptEx |
— |
+872 |
3,979 |
+28% |
— |